{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Novel Drug Development in CLL & HNL

Activity Steps

1 Activity
2 Take Test 3Certificate

Purpose of Activity

To provide information on the incidence of pneumonitis in a phase-II dose-escalation study of idelalisib and entospletinib for the treatment of chronic lymphocytic leukemia (CLL) and non Hodgkin lymphoma (NHL).

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Examine the design and outcomes of a phase-II dose-escalation study of idelalisib and entospletinib for the treatment of CLL and NHL.
  2. Recognize the incidence, diagnosis, and treatment of pneumonitis from the use of idelalisib/entospletinib.

Disclosures

All staff and planners, including spouses/partners (if any), in any position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.

Price: $17.95

Credits:

  • ANCC 1.5 CH
  • DC - BON 1.5 CH
  • KY-BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, #50-1223, Florida Board of Nursing, #50-1223, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.







Planner
Test Code: OT0716
Published: Jul 2016
Expires: 12/31/2026
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Robert H. Carlson
Categories: Cancer , Drug Therapy , Oncology
Specialties: Oncology
Topics: Cancer , Chemotherapy , Chronic Lymphocytic Leukemia (CLL) , Non Hodgkin Lymphoma (NHL)